Berkshire Hathaway Inc. remains a Buy with robust earnings, solid equities portfolio, and a strong cash position. Learn more ...

Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.

The conglomerate beat analysts' operating profit target, but there were no share buybacks over the third quarter.

Investors shouldn't replicate the concentration of Berkshire, but the following stocks could have a place in your portfolio.

Investors have long followed Buffett and team's stock picks via a massive portfolio within Berkshire Hathaway. Today, that ...

Shares of the Tylenol maker jumped by nearly one-fifth in premarket trading on the news that Kimberly-Clark (KMB) would ...

Berkshire Hathaway posts record Q3 2025 earnings as Warren Buffett prepares for succession. Discover key results, strategy, ...

Berkshire Hathaway shows strong profit growth, solid insurance and railroad performance, and a powerful cash position. Find ...

Berkshire Hathaway eschewed stock buybacks once again in the third quarter, while growing its cash pile further and driving ...

The biggest thing on most investors’ minds right now is that Buffett Vice Chair Greg Abel is set to succeed him as CEO in ...

The profits of Warren Buffett's company improved 17% as Omaha-based Berkshire Hathaway continues to prepare for the legendary ...

Berkshire Hathaway’s cash hoard soared to a record in the third quarter as the company's operating earnings also grew.